Branded Generics Market Boosted by Demand for Affordable Therapies

Branded Generics Market Size, Key Players with Forecast and Shares

The global branded generics market size is calculated at US$ 383.1 billion in 2025, grew to US$ 415.54 billion in 2026, and is projected to reach around US$ 867.21 billion by 2035. The market is expanding at a CAGR of 8.47% between 2026 and 2035.

The branded generics market is expanding due to increasing medical care expenses, the expiration of patents on blockbuster drugs, and patient and physician preferences for the perceived reliability of branded products over unbranded generics. North America is dominant in the market due to a growing aging population and cases of chronic diseases, while the Asia Pacific is the fastest-growing due to branded generics offering a more affordable substitute to expensive patented medication.

Key Takeaways

• Branded generics sector pushed the market to USD 383.1 billion by 2025.
• Long-term projections show USD 867.21 billion valuation by 2035.
• Growth is expected at a steady CAGR of 8.47% in between 2026 to 2035.
• Asia Pacific dominated the branded generics market in 2024, with a 38% share.
• North America is expected to grow at the fastest CAGR during the forecast period.
• By product type, the tablets & capsules segment dominated the market with 45% market share in 2024.
• By product type, the injectables segment is expected to grow at the fastest CAGR during the forecast period.
• By dosage form, the oral solid dosage segment dominated the market with a 50% share in 2024.
• By dosage form, the other innovative/advanced delivery segment is expected to grow at the fastest CAGR during the forecast period.
• By therapeutic area, the anti-infectives segment dominated the branded generics market with a 22% share in 2024.
• By therapeutic area, the oncology supportive/hematology segment is expected to grow at the fastest CAGR during the forecast period.
• By distribution channel, the retail pharmacies/drugstores segment dominated the market with a 42% share in 2024.
• By distribution channel, the online pharmacies/e-pharmacy platforms segment is expected to grow at the fastest CAGR during the forecast period.
• By end user, the outpatient/retail patients segment dominated the branded generics market with a revenue of 55% in 2024.
• By end user, the others segment is expected to grow at the fastest CAGR during the forecast period.

Executive Summary Table

What are Branded Generics?

The branded generics market covers instruments, consumables, software, and services used to detect, quantify, and characterize RNA molecules (mRNA, miRNA, lncRNA, circRNA, total RNA) across research, diagnostic, and industrial workflows. It includes technologies from RT-qPCR and digital PCR to bulk RNA-seq, single-cell RNA-seq, targeted RNA panels, microarrays, and emerging long-read / direct RNA sequencing.

Applications span gene expression profiling, biomarker discovery, drug development, clinical diagnostics, transcript isoform analysis, and regulatory/quality control in biomanufacturing. Demand is driven by precision medicine, single-cell biology, RNA therapeutics/vaccines, liquid biopsy development, and falling sequencing costs coupled with advanced bioinformatics.

Branded Generics Market Outlook

• Industry Growth Overview: The market is expected to surge rapidly between 2025 and 2034 due to increasing medical care expenditures, and there is rising pressure to find affordable alternatives to expensive brand-name drugs. Branded generics provide a balance between affordability and brand recognition.
• Global Expansion:  the worldwide growth of the pharmaceutical industries that sell off-patent drugs under proper brand names. North America and Asia-Pacific are the largest markets, with Asia-Pacific, specifically India and China
• Startup Ecosystem: A startup ecosystem is a network of patients, organizations, and startups partnering to create and scale novel companies. In the setting of branded generics, this ecosystem includes startup companies, investors, support organizations, and key players.

How AI is Revolutionizing the Branded Generics Market?

AI is transforming corporate development in the generics pharmaceutical industry from an art based on knowledge to a science grounded in data. As AI-powered tools become more user-friendly, even mid-sized and smaller generics companies are adopting them. Machine learning (ML), a major subset of AI, is emerging as the most supportive force in the industry. AI-driven algorithms examine thousands of data points from existing medicines to patents to create accurate formulations quickly.

Additionally, AI and automation improve documentation, reporting, and audit trails that are essential for government approval. Integrating AI and automation into the manufacturing of generic medicines is not only a technological upgrade; it signifies a shift in how healthcare reaches people, boosting the branded generics market.

Segmental Insights

Product Type Insights

Which Product Type is Dominating the Market?

The tablets & capsules segment accounted for 45% of the branded generics market share in 2024, as this form is typically more stable, providing longer shelf life and confrontation to environmental factors like moisture and temperature.  They are typically less luxurious to manufacture than other forms, making them more cost-effective for the end-user.

Injectables

The injectables segment is expected to grow at the fastest CAGR in the branded generics market during the 2025-2034 period, as branded generic injectable drugs provide many advantages over other administration routes, contributing precise and adjustable dosing, expected bioavailability, and onset of action.

Liquids & Suspensions

The liquids & suspensions segment is expected to grow at a significant CAGR during the forecast period, as it amplified viscosity of suspensions allows rapid swallowing, preventing the liquid from permeating all corners of the mouth and lowering the lingering aftertaste often associated with solution formulations. Formulating liquid suspensions contributes a slight interaction of science and creativity.

Dosage Form Insights

What made the Dosage Form Segment Dominant in the Market in 2024?

The oral solid dosage segment accounted for 50% of the branded generics market revenue in 2024, as oral solid dosage forms enable specific dosing and confirm the correct delivery of the prescribed amount of drugs. They offer uniform drug content, reducing variations in dosage and improving consistency in drug delivery.

Other Innovative/Advanced Delivery

The other innovative/advanced delivery segment is expected to grow at the fastest CAGR in the branded generics market during the 2025-2034 period, as these systems are intended to transport medications exactly to the target site, reducing adverse effects and enhancing patient compliance. The significance of these innovations lies in their capabilities to offer more efficient treatments for different medical conditions.

Liquid Oral

The liquid oral segment is expected to grow significantly during the forecast period as these dosage forms are better than tablets or other solid drugs for patients who have trouble swallowing. They are a standard choice for elderly and children patients. Liquids are absorbed rapidly than solids in the body fluids and provide more elasticity in attaining the correct dosage of medication.

Therapeutic Area Insights

Which Therapeutic Area Dominated the Market in 2024?

The anti-infectives segment dominated the Branded Generics Market, accounting for 22% of revenue in 2024, as anti-infective therapies are applied to a broad range of diseases, from minor infections to serious and life-threatening diseases like pneumonia, meningitis, and tuberculosis.  By addressing the root cause of an infection, these drugs improve symptoms such as fever and pain, helping patients feel better and recover rapidly.

Oncology Supportive / Hematology

The oncology supportive/hematology segment is expected to grow at the fastest CAGR in the branded generics market during the 2025-2034 period, as generic drugs lower the cost of care predominantly, and their multi-source origin often provides a guarantee in supply. The applications of generic and biosimilar products are hinged on the supposition that they are of a certain quality and of similar pharmaceutical truthfulness as their modernizer counterparts.

Cardiovascular

The cardiovascular segment is expected to grow at a significant CAGR during the forecast period, as generic CVD drugs show the same medical output as brand-name medications. Generic medications provide considerably potential cost savings to health systems than the branded counterparts.

Distribution Channel Insights

Which Distribution Channel Dominated the Market in 2024?

The retail pharmacies/drugstores segment dominated the branded generics market, accounting for 42% of share in 2024, as retail pharmacies play a significant role in medical care by offering convenient access to medications, a broad range of products, and significant additional solutions. Retail pharmacies have their wide range of services and products.

Online Pharmacies / E-pharmacy Platforms

The online pharmacies/e-pharmacy platforms segment is expected to grow at the fastest CAGR in the branded generics market during the 2025-2034 period, as these types of pharmacies often offer inexpensive pricing, discounts, and generic substitutes, leading to potential cost savings for people. This affordability is specifically relevant for those with chronic health conditions who need long-term drug treatment. Online pharmacies offer an extensive database of medication information, providing both healthcare professionals and patients with access.

Hospital Pharmacies / Institutional Tender

The hospital pharmacies/institutional tender segment is expected to grow at a significant CAGR during the forecast period, as hospital pharmacy is a dedicated field of pharmacy that is combined with the care of a medical center. These involve centers such as an outpatient clinic, hospital, drug-dependency facility, poison control center, drug information center, or residential care solutions.

End User / Customer Insights

Which End User / Customer Dominated the Market?

The outpatient/retail patients segment dominated the branded generics market, accounting for 55% of revenue in 2024, as outpatient care centers provide wellness and prevention solutions, diagnostic services, management, and rehabilitation to patients. Outpatient services are cost-effective, and major treatment centers offer limited-scale outpatient fees.

Others (Veterinary, Institutional)

The others segment is expected to grow at the fastest CAGR during the forecast period, as veterinary generic drugs provide advantages like guaranteed efficacy and quality through a rigorous approval procedure, constant production, and marketing support.

Long-term Care & Nursing Homes

The academic & research institutes segment is expected to grow at a significant CAGR in the branded generics market during the 2025-2034 period, as generic drugs in long-term care (LTC) offer major advantages such as cost savings, enhance patient adherence, and improve access to efficient treatment. Generic drugs also increased accessibility, healing equivalence, and trustworthy safety and quality.

Regional Insights

Asia Pacific: Increasing Collaboration among the Healthcare Organizations?

Asia Pacific dominated the branded generics market in 2024 with approximately 38% share, driven by the growing burden of long-term diseases, rising medical care spending, and the need for affordable, high-quality medicines. Growing government support also drives market growth; for instance, in February 2025, China initiated a volume-based procurement (VBP) policy to award drug companies with large sales opportunities at significantly lower prices. Oftentimes, VBP winners have drug price discounts of 50% to 90%. There have been 10 rounds of VBP for drugs to date.

For Instance,

• In October 2025, Novartis announced that it had agreed to acquire Avidity Biosciences, Inc., a San Diego-based biopharmaceutical company focused on a new class of therapeutics allowing RNA delivery to muscle. The acquisition will follow the separation of Avidity’s early-stage precision cardiology programs.

Rising chronic disease burden in India

In India rising prevalence of lifestyle-related and long-term diseases is the major driver of the market growth. Rising public and private healthcare investment in India is creating a massive base of patients with access to healthcare treatment. This branding shapes trust with both physicians and patients, who often trust that these products are of higher quality than unbranded substitutes.

For Instance,

• In June 2025, over 16,900 Jan Aushadhi Kendras (JAKs) opened, offering 2,110 generic medicines and 315 surgical products under the scheme, it implemented by the Ministry of Health and Family Welfare, with support from the National Pharmaceutical Pricing Authority.

Why is North America the Fastest-Growing in the Branded Generics Market?

North America is estimated to host the fastest-growing branded generics market during the forecast period as a combination of massive healthcare expenditure, a strong government environment that supports generic use, and significant market consolidation. High medical care investment and the structure of insurance programs such as Medicare and Medicaid offer strong incentives for generic drug use.

For Instance,

• In October 2025, the U.S. Food and Drug Administration (FDA) announced a pilot program to prioritize the review of abbreviated new drug applications (ANDAs) from generic drug companies that conduct both manufacturing and testing in the United States. The initiative aims to strengthen domestic drug production and secure the U.S. pharmaceutical supply chain.

Growing Innovation in Branded Generic Drugs: A Major Market Driver in the U.S.

In the U.S., the presence of a large and increasing aging patient population with chronic illnesses such as cardiovascular disease and diabetes creates sustained demand for cost-effective solutions. Increasing innovation in novel product launches by various healthcare companies. For Instance, in April 2025, Glenmark's US arm launched a generic Adderall for ADHD in May 2025 to address shortages, targeting a $421.7 million market.

Europe: Increasing Government Support in Europe?

Europe is expected to grow at a significant CAGR in the branded generics market during the forecast period, as European governments are under continuous pressure to manage rising healthcare expenses and are vigorously endorsing generics to attain this. Many countries are realizing guidelines that promote the use of generics, with prescribing mandates and substitution incentives, which contribute to the growth of the market.

Why Increasing Spending on Healthcare Services in the UK?

In the UK, branded generics, which are off-patent drugs sold under a brand name, hold noteworthy value in the UK due to doctors' and patients' trust in their consistency and quality. For long-term therapies, particularly for chronic conditions such as cardiovascular and endocrine disorders, prescribing branded generics improves patient adherence.

For Instance,

• In June 2025, the UK government doubled the rate that pharmaceutical companies must repay on the sales of newer products to the NHS under the statutory scheme for branded medicines in the second half of 2025, to a record 31.3%.

Surging Branded Generics in South America

In South America, branded generics thrive due to cost-sensitive markets and patent expirations. Governments in Argentina and Chile support local manufacturing, boosting competition and affordability while maintaining brand loyalty among prescribers.

Brazil’s Domestic Pharma Dominance

Brazil’s branded generics market expands rapidly as ANVISA streamlines approvals. Strong domestic players like EMS and Eurofarma leverage marketing strength and biosimilar introductions, driving double-digit growth amid economic stabilization.

MEA’s Accessibility-Driven Expansion

Across the Middle East and Africa, branded generics grow through enhanced healthcare access and local production incentives. Egypt, Nigeria, and Kenya witness rising demand as governments prioritize affordable chronic disease treatments.

GCC’s Quality-Preferred Market Shift

In GCC countries, branded generics gain traction as physicians prefer trusted brands over unbranded versions. Saudi Arabia and UAE lead adoption, supported by localization policies and robust multinational–local manufacturer collaborations.

Branded Generics Market – Value Chain Analysis

R&D

The R&D process for branded generics is a strategic, reverse-engineering strategy that develops a bioequivalent, cost-effective form of an innovator drug once its patent expires.

Key Players: Teva and Viatris

Clinical Trials

Clinical trials for branded generics mostly involve bioequivalence research, which is a type of clinical trial intended to prove that the generic drug is substitutable with the original branded drug.

Key Players: Sun Pharma and Dr. Reddy's Laboratories

Patient Services

Patient services for branded generics are intended to build brand recognition, improve patient confidence, and enhance treatment adherence, which is specifically important since branded generics carry a brand name but not the innovator's premium price.

Key players: Lupin Limited and Zydus Lifesciences

Company Landscape

Sandoz Group AG

Company Overview

Corporate Information, Headquarters, Year Founded, Ownership Type:

• Headquarters, Basel, Switzerland.
• Year Founded, 1886 (original Sandoz), spun off as Sandoz Group AG in 2023.
•  Ownership Type: Publicly listed company, pure-play off-patent firm after spin-off from Novartis.

History and Background:

• Traces its roots back to the 1886 chemical company Kern & Sandoz in Basel.
• Became a part of Novartis in 1996 through the merger of Sandoz and Ciba-Geigy.
• Operated as the generics and biosimilars division of Novartis until its spin-off in October 2023.

Key Milestones/Timeline:

• 1886, Foundation of the original Sandoz in Basel, Switzerland.
• 1996, Merged with Ciba-Geigy to form Novartis, becoming its generic division.
• 2003, Novartis consolidates its generics businesses under the Sandoz brand.
• October 2023, Successfully spun off from Novartis, listing on the SIX Swiss Exchange as Sandoz Group AG, establishing itself as a standalone pure-play generics and biosimilars company.

Business Overview

Business Segments/Divisions:

• Generics: Focuses on generic drugs across various therapeutic areas.
• Biosimilars: Pioneer in the development and commercialization of biosimilars, offering cost-effective alternatives to expensive biologic drugs.

Geographic Presence:

Extensive global reach, with a strong presence in the United States and Europe, serving over 100 countries.

Key Offerings:

• A broad portfolio of generic pharmaceuticals (oral solids, sterile injectables, respiratory, ophthalmics).
• Biosimilars (e.g., in oncology, immunology, and endocrinology).
• Branded generics, which are generic drugs marketed under a brand name.

End-Use Industries Served:

• Hospitals, Retail Pharmacies, Health Systems, Patients, and Healthcare Providers globally.
• Key Developments and Strategic Initiatives 

Mergers & Acquisitions:

Focus on strategic acquisitions to strengthen the biosimilars portfolio and market reach.

Partnerships & Collaborations:

• Continuously seeks strategic partnerships to enhance its portfolio and expand geographical footprint.
• Recent Example (2024), Teva and Sandoz announced a strategic collaboration to co-develop and commercialize 30 generic products in the U.S. and Europe, aiming to reduce R&D costs and enhance market presence.

Product Launches/Innovations:

• Ongoing launches of generic and biosimilar medicines following patent expiries.
• Launch of new biosimilar products in key therapeutic areas like immunology and oncology.

Capacity Expansions/Investments:

Investments in manufacturing and supply chain to improve efficiency and reliability post-spin-off.

Regulatory Approvals:

Secures multiple FDA and EMA approvals for generic and biosimilar products annually, a core part of its business.

Distribution channel strategy:

• Direct sales to hospitals and institutions, wholesalers, and retail pharmacies, leveraging its global supply chain network.
• Technological Capabilities/R&D Focus

Core Technologies/Patents:

Expertise in complex generics (e.g., injectables, inhalation) and high-quality biosimilar development, manufacturing, and analytical techniques.

Research & Development Infrastructure:

Dedicated R&D infrastructure focused on difficult-to-make generics and biosimilars, distinct from the former Novartis innovative R&D.

Innovation Focus Areas:

• Biosimilars development is a key priority for future growth.
• Complex generics, including technologies like sterile injectables and specialized dosage forms.
• Competitive Positioning

Strengths & Differentiators:

• Global Scale and Reach as a pure-play off-patent firm.
• Market Leader in Biosimilars, a high-growth, high-margin segment.
• Strong Brand Reputation inherited from Novartis for quality and reliability.

Market presence & ecosystem role:

Major global supplier of affordable medicines, playing a critical role in increasing patient access, particularly in Europe and the U.S.

SWOT Analysis:

• Strengths: Strong biosimilar pipeline, Established global regulatory expertise, High-quality manufacturing standards.
• Weaknesses: Dependence on competitive generics pricing pressure, Need to rebuild full corporate functions post-spin-off.
• Opportunities, a Large patent cliff providing new targets for generics and biosimilars, and Expansion into emerging markets.
• Threats, Aggressive competition from other large generic players (e.g., Teva, Viatris), and intensifying regulatory scrutiny and approval timelines.

Recent News and Updates

Press Releases:

• Mid-2024, Announcement of strong financial performance driven by biosimilars and volume growth in Europe.
• Late 2024, Sandoz emphasizes its commitment to Environmental, Social, and Governance (ESG) targets post-spin-off.

Industry Recognitions/Awards:

Recognized for contributions to healthcare affordability and for its biosimilar portfolio leadership.

Teva Pharmaceutical Industries Ltd.

Company Overview

Corporate Information, Headquarters, Year Founded, Ownership Type:

• Headquarters, Tel Aviv, Israel.
• Year Founded, 1901.
• Ownership Type: Publicly traded multinational pharmaceutical company.

History and Background:

• Founded in Jerusalem as a small wholesale drug business.
• Grew through a series of mergers and acquisitions, notably the acquisition of Barr Pharmaceuticals in 2008 and Allergan's generic division in 2016, becoming a global generics powerhouse.
• Has a long history as a pioneer in the global generic drug industry.

Key Milestones/Timeline:

• 1901, Founded in Jerusalem.
• 1976, Became Teva Pharmaceutical Industries Ltd.
• 2008, Acquired Barr Pharmaceuticals, significantly boosting its U.S. generic presence.
• 2016, Acquired Allergan's generics business (Actavis Generics), solidifying its position as a global generics leader.
• 2019-Present, Focus on debt reduction, operational efficiency, and stabilizing the business after a period of high debt and legal challenges.

Business Overview

Business Segments/Divisions:

• North America, Europe, International Markets (covering global generics, specialty medicines, and over-the-counter products).
• Generics: Leading provider of generic and branded medicines.
• Specialty Medicines: Focuses on proprietary and innovative products, particularly in CNS (Central Nervous System) and respiratory.

Geographic Presence:

Operates in over 60 countries, with manufacturing facilities and commercial operations worldwide. Strong market penetration in the U.S. and Europe.

Key Offerings:

• The world's largest portfolio of generic medicines, including complex generics and branded generics.
• Specialty drugs like Copaxone (multiple sclerosis) and AUSTEDO (neurological disorders).
• Over-the-counter (OTC) products.

End-Use Industries Served:

Wholesalers, retail drugstores, hospitals, clinics, and government agencies.

Key Developments and Strategic Initiatives

Mergers & Acquisitions:

In the current phase, focus is on integrating past large acquisitions and smaller, strategic acquisitions to fill portfolio gaps.

Partnerships & Collaborations: 

• Recent Example (2024), Teva announced a strategic collaboration with Sandoz to co-develop and commercialize 30 generic products in the U.S. and Europe, leveraging combined R&D strengths.
• Partnerships for biosimilar development and commercialization.

Product Launches/Innovations:

• Continuous launch of new generic products, focusing on complex generics and products with high barriers to entry.
• Launch of new proprietary products, like biosimilars and new indications for specialty drugs.

Capacity Expansions/Investments:

Ongoing optimization of its global manufacturing network to improve efficiency and reduce costs.

Regulatory Approvals:

Secures a high volume of generic drug approvals (Abbreviated New Drug Applications, ANDAs) from the FDA and equivalent bodies globally.

Distribution channel strategy:

Mix of direct distribution and partnerships with major drug wholesalers and pharmacy benefit managers (PBMs) to ensure broad market access and managed care coverage.

Technological Capabilities/R&D Focus

Core Technologies/Patents:

• Deep expertise in complex formulation and high-tech generic development, including injectables, respiratory products, and transdermal patches.
• Focus on specialty drug R&D in CNS and respiratory.

Research & Development Infrastructure: 

Global R&D centers dedicated to generic drug formulation, biosimilar development, and specialty pipeline advancement.

Innovation Focus Areas:

• Specialty Drug R&D in niche areas, providing higher margins.
• Biosimilars, to compete in the growing biologics market.
• Advanced generic delivery systems and complex molecules.

Competitive Positioning

Strengths & Differentiators:

• Vast Portfolio and Pipeline, one of the largest in the industry.
• Strong U.S. Market Position in generics.
• Integrated Model combining Generics and Specialty Pharmaceuticals.

Market presence & ecosystem role:

A critical global player in supplying high volumes of essential, affordable generic medications, with a strong focus on maximizing generic market penetration.

SWOT Analysis:

• Strengths: Global manufacturing and supply chain scale, Market leadership in U.S. generic prescriptions, Stabilized financial position with debt reduction efforts.
• Weaknesses: High historical debt burden, Exposure to generic pricing erosion, and Ongoing high-profile legal matters (e.g., opioid litigation).
• Opportunities, Strong specialty pipeline in CNS, Launch of new complex generics and biosimilars, Growth in branded generics in emerging markets.
• Threats, Intense competition, and pricing pressure in the core generic market, Successful specialty product patent challenges, and Regulatory compliance risks.

Recent News and Updates

Press Releases:

• Q1 2024, Announcement of solid financial results, continuing momentum in revenue and operating income, often exceeding analyst expectations.
• 2024/2025, Updates on progress regarding legal settlements and the ongoing strategy to focus on profitable growth and R&D investment.

Industry Recognitions/Awards:

Recognized for its volume contribution to affordable healthcare globally and for key product innovation in specialty areas.

Top Vendors in the Market & Their Offerings

Top Companies in the Branded Generics Market

• Sun Pharmaceutical Industries Ltd.
• Sandoz (Novartis)
• Teva Pharmaceutical Industries Ltd.
• Viatris (Mylan/Upjohn)
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Lupin Ltd.
• Aurobindo Pharma Ltd.
• Zydus Cadila (Cadila Healthcare Ltd.)
• Glenmark Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Mankind Pharma Pvt. Ltd.
• Abbott Laboratories
• Pfizer Inc.
• Hikma Pharmaceuticals plc
• Jubilant Life Sciences / Jubilant Pharma
• Alembic Pharmaceuticals Ltd.
• Emcure Pharmaceuticals Ltd.
• Natco Pharma Ltd.
• Aspen Pharmacare Holdings Ltd.

Read further to see how top players are shaping the future of branded generic market at: https://www.towardshealthcare.com/companies/branded-generics-companies

Recent Developments in the Branded Generics Market

• In October 2025, Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced expansion of its strategic collaboration with Civica, Inc. to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing the supply of high-quality, affordable insulins.
• In October 2025, Viatris Inc., a global healthcare company, announced it had acquired Aculys Pharma, Inc., a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia®, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in Japan. 
• In September 2025, ITOCHU Corporation announced that it had agreed with AND PHARMA Co., Ltd., a pharmaceutical industry group focused on pharmaceutical manufacturing, to acquire shares in AND PHARMA and make it one of its equity-method affiliates.
• In August 2025, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the FDA approval and U.S. launch of a generic version of Saxenda (liraglutide injection). This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy.

Segments Covered in the Report

By Product Type

• Tablets & Capsules
  • Immediate-release tablets
  • Controlled-release tablets
• Injectables
  • Vials/ampoules
  • Pre-filled syringes
• Liquids & Suspensions
  • Bottled syrups
  • Suspensions / pediatric formulations
• Topicals & Dermatologicals
  • Creams/ointments
  • Gels/patches
• Inhalation & Nasal
  • Inhalers/nebulizer solutions
  • Nasal sprays
• Others 
  • Ophthalmic drops
  • Suppositories / specialized forms

By Dosage Form

• Oral Solid Dosage
• Parenteral / Injectables
• Liquid Oral
• Topical / Transdermal
• Inhalation / Nasal
• Other Innovative/Advanced Delivery

By Therapeutic Area

• Anti-infectives
  • Systemic antibacterials
  • Antiviral generics
• Cardiovascular
• Central Nervous System
• Diabetes & Endocrine
• Pain & Anti-inflammatories
• Gastrointestinal
• Respiratory
• Oncology Supportive / Hematology
• Others

By Distribution Channel

• Retail Pharmacies / Drugstores
  • Chain pharmacy networks
  • Independent retail outlets
• Hospital Pharmacies / Institutional Tender
• Online Pharmacies / E-pharmacy Platforms
• Government Procurement / Public Health Programs
• Other Channels

By End-User Industry / Customer

• Outpatient / Retail Patients
• Hospitals / Inpatient Care
• Long-term Care & Nursing Homes
• Government / Public Health Programs
• Others

By Region

• North America
  • U.S.
  • Canada 
  • Mexico
  • Rest of North America
• South America 
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe 
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe 
  • Austria
  • Russia & Belarus
  • Türkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific 
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA 
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
• South Africa
• Egypt
• Rest of MEA